<DOC>
	<DOCNO>NCT00579709</DOCNO>
	<brief_summary>The research purpose determine thymus transplantation immunosuppression safe effective treatment complete DiGeorge anomaly . The research include study evaluate whether thymus transplantation result complete DiGeorge anomaly subject develop normal immune system .</brief_summary>
	<brief_title>Thymus Transplantation With Immunosuppression</brief_title>
	<detailed_description>DiGeorge anomaly complex cardiac defect , parathyroid deficiency , thymus absence , result profound T-cell deficiency . There spectrum disease DiGeorge anomaly respect three defect . For complete DiGeorge anomaly subject severe T cell defect , PI show thymus transplantation safe efficacious without pretransplantation immunosuppression pretransplantation Thymoglobulin cyclosporine . Some DiGeorge patient poor T cell function risk death infection immune problem ; however , patient enough T cell function reject graft . This protocol design patient . Atypical phenotype typical phenotype DiGeorge subject include protocol . Atypical complete DiGeorge anomaly patient rash , lymphadenopathy , oligoclonal T cell proliferation . The T cell marker thymic function ( co-express CD45RA CD62L ; contain T cell receptor rearrangement excision circle , TRECs ) . Typical complete DiGeorge anomaly patient protocol whose PHA response &gt; 20 fold . Although patient low T cell function , may enough reject transplant , Thymoglobulin use .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<criteria>Transplant Inclusion No age limit Thyroid study must do abnormal , must therapy DiGeorge diagnosis must 1 symptom follow list : Heart defect Hypocalcemia require replacement 22q11 hemizygosity 10p13 hemizygosity CHARGE association Abnormal ears plus mother diabetes ( type I , type II , gestational ) Atypical Diagnosis : Must , , rash . If rash present , biopsy rash must show T cell skin . If rash &amp; adenopathy resolve , must still oligoclonal T cell . Within 1 month tx must PHA response &gt; 20 fold background &gt; 5,000 cpm , whichever high , response &lt; . Circulating CD3+ T cell &gt; 50/mm3 CD45RA+CD62L+CD3+ T cell &lt; 50/mm &lt; 5 % CD3 count , whichever high ( must do 2x ) Immunoscope &gt; 40 % oligoclonal TCRBV family . A 2nd test per sponsor discretion T cell number increase activation status change . If TREC do pretx must TRECs &lt; 100 per 100,000 CD3+ cell . Typical Diagnosis : Circulating CD3+ CD45RA+ CD62L+ T cell &lt; 50/mm3 &lt; 5 % total T cell PHA response &gt; 20 fold background &gt; 5,000 cpm , whichever high . 2 study must show similar immunological finding qualify study . TRECs , do , &lt; 100/100,000 CD3 cell Transplant Exclusion : Heart surgery &lt; 4 week pretx date Heart surgery anticipate w/in 3 month propose tx Rejection surgeon anesthesiologist surgical candidate Lack sufficient muscle tissue accept 0.2 grams/kg transplant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Thymus Transplantation</keyword>
	<keyword>DiGeorge Anomaly</keyword>
	<keyword>DiGeorge Syndrome</keyword>
	<keyword>Athymia</keyword>
	<keyword>Low T cell number</keyword>
	<keyword>Immunoreconstitution</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Complete DiGeorge</keyword>
	<keyword>Typical DiGeorge</keyword>
	<keyword>Atypical DiGeorge</keyword>
	<keyword>Complete DiGeorge Anomaly</keyword>
</DOC>